Table A2.

Dose Adjustments in Response to Neutrophil and Platelet Nadir Counts of Previous Cycle

Grade	Neutrophil Nadir (/mm3)	Platelet Nadir (/mm3)	Timing	Dose*
1	≥ 1,500	≥ 75,000	Treat on time	No change
2	1,000 to < 1,500	50,000 to < 75,000	Treat on time if recovered	No change
≥ 3	< 1,000	< 50,000	Resume treatment when neutrophil count is ≥ 1,000 and platelet count is ≥ 75,000, if the dose was interrupted during the dosing period (days 1-21); treat on time for subsequent cycles if counts have recovered by planned next day 1	Decrease by one dose level†

NOTE. Study drug was held if a participant developed neutrophil count < 1,000/μL or platelet count < 50,000/μL at any time during study drug dosing. Study drug was restarted as per Table A2.

^*When calculating dose modifications, choose most severe toxicity.

^†Dose reductions below dose level − 3 were not allowed; if dose reductions below dose level − 3 were required, study drug administration was discontinued.